Active substanceMagaldratMagaldrat Similar drugsTo uncover RioFast suspension inwards Takeda GmbH Germany RioFast pills inwards Takeda GmbH Germany Dosage form: & nbspchewing tablets. Composition:1 chewable tablet contains:Active ingredient: 800 mg of magdrate (corresponding to 22.6 mEq of hydrochloric acid);Excipients: sorbitol - 718.2 - 829.3 mg; Macrogol 4000 to 240.0 mg; maltol - 1.0 mg; flavoring caramel 45-8059-02 - 23.6 mg; flavoring cream 49930 - 6.4 mg; calcium behenate-10,8 mg. Description:RioFast, chewable tablets 800 mg: from white to light beige, round plano-cylindrical tablets with impregnations, chamfer on both sides and smell of caramel. On one side of the tablet is an engraving "800". Pharmacotherapeutic group:An antacid. ATX: & nbspA.02.A.D.02 Magaldrat Pharmacodynamics:The mechanism of action of the magic is based on the instant regulation of the acidity of the gastric juice. RioFast has an antacid effect that depends on the dose and pH: reduces the amount of acid and simultaneously binds pepsin, bile acids and lysolecithin, thus reducing the corrosive effect of gastric juice.The magadrate is a stable substance with a certain lattice-layered crystal structure and contains hydroxides in one molecule of aluminum and magnesium.The antacid effect is due to the neutralization of protons by sulfate and hydroxide ions located at the nodes of the lattice structure. After neutralization, the lattice structure of the magdalite is destroyed. Magadrat does not affect gastric motility. Due to the fact that the drug maintains the pH in the therapeutically optimal range (pH 3 - 5) for 20-40 min, it does not cause an acid ricochet. The drug does not contain sugar and contains a low amount of sodium. 800 mg of anhydrous magdalite neutralizes 18-25 mEq of hydrochloric acid. Pharmacokinetics:Magadrat is not absorbed in the gastrointestinal tract (GIT). During the neutralization process - acids are released small amounts of magnesium and aluminum ions, which when passed through the intestine turn into hardly soluble phosphates and then is excreted by the intestine. Some of the ions are suctioned. It was observed an increase in the level of aluminum ions in the blood plasma even in patients with normal renal function. Long-term use of preparations containing aluminum can cause a decrease in phosphate absorption. Indications:- Heartburn;- acid-dependent diseases of the gastrointestinal tract (erosive gastroduodenitis, gastro-and duodenopathy, caused by the use of non-steroidal anti-inflammatory drugs, stress ulcers, Zollinger-Ellison syndrome, gastroesophageal reflux disease disease);- symptomatic therapy of peptic ulcer of stomach and duodenum. Contraindications:- hypersensitivity to the components of the drug;- children under 15 years;It is not recommended to use the drug in patients with hereditary intolerance to fructose. Pregnancy and lactation:During pregnancy, the drug should be administered only for a short time to avoid the penetration of aluminum ions into the fetal tissues. During the period of thoracic feeding the drug should be taken with caution, due to the possible exclusion of aluminum ions in breast milk. However, due to the low absorption of the drug, the negative impact on the baby is not proven. Dosing and Administration:Tablets are thoroughly chewed, and then washed down with a small amount of liquid or kept in the mouth until completely dissolved. The drug is taken 1 hour after eating and immediately before going to sleep on D-2 tablets for a short time for symptomatic therapy. The maximum daily dose for adults and children from 12 years: 6400 mg of magadrate per day (8 chewable tablets). If the symptoms do not disappear for more than 2 weeks during drug therapy, a clinical examination of the patient should be performed to exclude the presence of a malignant disease. In elderly patients, dose adjustment is not required. Side effects: The following categories are used to classify the frequency of undesirable effects: Very frequent (> 10%), Frequent (> 1% - <10%), Infrequent (> 0.1% - <1%), Rare (> 0.01% - < 0.1%), Very rare, including individual reports (<0.01%). From the digestive system:Frequent: unformed stool;Very rare: diarrhea. Due to prolonged use in high doses, as well as in patients with renal insufficiency, the drug can cause an increase in the concentration of aluminum and magnesium ions in the blood, which can lead to the deposition of aluminum, mainly in the nervous and bone tissues, and also to a decrease in phosphate content in bone tissue. Sorbitol, which is part of the drug, can cause digestion and diarrhea. Overdose:There were no cases of overdose. Due to the fact that - the active component does not dissolve at pH values above 5, intoxication by the drug due to an overdose is unlikely. Interaction:Due to the fact that antacids can reduce the absorption of other drugs in a joint application, the interval between the taking of the drug Riofast and other drugs should be at least 2 hours.Taking antacids can significantly reduce the absorption of antibiotics. As a result, antacids are not recommended for antibiotic therapy.With simultaneous use with digoxin, isoniazid, iron compounds and chlorpromazine, RioFast can cause a slight decrease in absorption of these drugs.RioFast can potentiate the anticoagulant effect of coumarin derivatives.The drug should not be taken with beverages that have acid properties (for example, fruit juices, wine), as well as with effervescent tablets containing citric or tartaric acid, due to increased intestinal absorption of aluminum ions. Special instructions:Due to the possible relationship between elevated plasma concentrations of aluminum and the development of encephalopathy, special attention should be given to patients on dialysis. In patients with impaired renal function (creatinine clearance less than 30 ml / min), the RioFast must be taken with constant monitoring of the content of aluminum and magnesium ions in the blood plasma. The concentration of aluminum ions in the blood plasma should not exceed 40 ng / ml. In the case of permanent or often recurring disorders, it is necessary to establish the cause of relapse, that is, the presence of the underlying disease.Patients with peptic ulcer or duodenal ulcer should be tested for Helicobacter pylori. If the test is positive, standard therapy for eradication should be performed Helicobacter pylori.The drug does not contain sugar and can be used in patients with diabetes mellitus.1 tablet contains about 0.774 g of sorbitol, which corresponds to about 6.2 g of sorbitol taken daily. Form release / dosage:Tablets chewing 800 mg. Packaging:For 10 tablets in a blister of PVC / PVDC-AL; 1 or 2 blisters together with instructions for use are placed in a cardboard box. Storage conditions:At a temperature not higher than 30 ° C. Keep out of the reach of children. Shelf life:3 years.The drug can not be used after the expiration date. Terms of leave from pharmacies:Without recipe Registration number:LP-000700 Date of registration:28.09.2011 The owner of the registration certificate:Takeda GmbHTakeda GmbH Germany Manufacturer: & nbspTAKEDA, GmbH Germany Representation: & nbspTAKEDA TAKEDA Japan Information update date: & nbsp12/23/2013 Illustrated instructions × Illustrated instructions Instructions